- 专利标题： METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
-
申请号： EP18161154.2申请日： 2008-05-30
-
公开(公告)号： EP3392273A1公开(公告)日： 2018-10-24
- 发明人: CHU, Seung Yup , DESJARLAIS, John R. , KARKI, Sher Bahadur , LAZAR, Gregory Alan , MOORE, Gregory , VOSTIAR, Igor
- 申请人： Xencor, Inc.
- 申请人地址： 111 W. Lemon Avenue Monrovia, CA 91016 US
- 专利权人： Xencor, Inc.
- 当前专利权人： Xencor, Inc.
- 当前专利权人地址： 111 W. Lemon Avenue Monrovia, CA 91016 US
- 代理机构： Kransell & Wennborg KB
- 优先权： US940776P 20070530; US953174P 20070731; US970413P 20070906; US976279P 20070928; US990509P 20071127; US12035P 20071206; US13775P 20071214; US19395P 20080107; US32059P 20080227; US43585P 20080409; US46397P 20080418
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; C07K16/00
摘要：
An antibody having affinity for CD40 on a B cell or dendritic cell, wherein the antibody comprises at least the amino acid substitution S267E in the Fc region as compared to a parent Fc region, wherein the numbering is according to the EU index, as in Kabat, wherein the antibody has an enhanced binding affinity to FcyRllb, and wherein the antibody activates the B cell or dentritic cell.
A pharmaceutical composition comprising the above antibody and a pharmaceutically acceptable carrier. A method of activating a B cell or dendritic cell comprising contacting the B cell or dendritic cell with the above antibody.
A pharmaceutical composition comprising the above antibody and a pharmaceutically acceptable carrier. A method of activating a B cell or dendritic cell comprising contacting the B cell or dendritic cell with the above antibody.
信息查询
